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Cu-ATSM is an emerging radiopharmaceutical for diagnostic use in Positron Emission 
Tomography (PET) and has potential utility for radiation therapy but to date there are no studies 
that assess the occupational doses delivered to workers in either a hospital or veterinary 
environment. This study consisted of canine patients that were recruited at the Colorado State 
University James L. Voss Veterinary Teaching Hospital (VTH). The study was aimed at 
determining the radiation dose to veterinary workers from clinical PET/CT procedures using 
64
Cu-ATSM. To determine the dose to the workers, each worker was assigned two Electronic 
Personal Dosimeters (EPDs) to be worn on the chest and waist during the entirety of each 
procedure. The workers monitored during this study involved included a radiobiologist, a nuclear 
medicine technician, an anesthesiologist, and a veterinary surgeon. Seven canine patients were 
imaged over a ten month period with an average mass of 33.7 kg (a range of 20.0 – 55.1 kg) with 
an average injected activity of 5 MBq kg
-1
. The dose range for the radiobiologist was 2 -17 µSv, 
for the nuclear medicine technician 0 -14 µSv, for the anesthesiologist 0 – 12 µSv, and for the 
surgeon 0 -10 µSv. In a comparison between the results of this study and published literature on 
occupational exposures from human/veterinary FDG PET/CT procedures, 
64
Cu-ATSM 
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Background and Motivation 
              Positron emission tomography (PET) is one of multiple nuclear medicine imaging 
techniques. The concept of PET was introduced in the 1950s but the first PET procedure was not 
documented until 1970 [1-2]. While in its early stages, PET was primarily used only for research 
purposes, but with the advancement of technology, PET was adopted for use in the medical field. 
Over the years PET has proved itself useful in many aspects of medicine but especially in the 
discipline of oncology. PET has distinct advantages over other diagnostic imaging modalities. 
The main advantage of PET is the ability to provide functional and metabolic information. PET 
has a distinct edge over imaging modalities such as computed tomography (CT) and magnetic 
resonance imaging (MRI) in the staging, diagnosis, and prognosis of malignant processes due to 
the ability to provide metabolic information [3-4].  
              PET is typically combined with CT. The CT provides anatomical information and the 
PET data is then combined with the CT scans, allowing simultaneous viewing of physiological 
and anatomical characteristics of the region of interest. The technique of combining PET with 
CT allows more information to be gathered than either PET or CT could provide separately 
because the combination of CT data improves the anatomic localization of the metabolic acuity 
provided by PET. Fusing PET with CT data also helps correct for attenuation based on tissue 
density values derived from the CT scans.  An example of CT and PET/CT is shown below in 
Figure 1. Figure 1 demonstrates the effectiveness of fusing PET and CT by showing areas of 






Figure 1: Example of PET/CT – Left: Illustration how CT effectively describes the anatomy of a 
patient. Right: Example of how fusing metabolic information gathered from PET with CT can 
increase the clinical significance of the image. The central area of the tumor with decreased 
metabolic activity derived from PET indicates the necrotic nature of the tumor. 
The clinical benefits and widespread use of PET/CT has resulted in a growth in popularity over 
the past decade. PET/CT became available clinically in 2001 and has since become a standard 
medical diagnostic procedure. Approximately 1.25 million PET or PET/CT scans were 
performed in the United States in 2005 according to the Society of Nuclear Medicine and 
Molecular Imaging.  The 2011 IMV Imaging Market Report stated that approximately 1.75 
million PET or PET/CT scans were performed annually (0.5 million more than in 2005) and on 
average 140-160 new PET/CT units are being purchased and installed each year in order to meet 
the continual rise in demand for PET/CT procedures. 
Positron Emission Tomography in Veterinary Medicine 
              The increasing popularity of PET/CT in human medicine combined with the growing 
number of new PET studies over the past decade has caused the veterinary community to 
consider the benefits of PET/CT [5-6]. Veterinary clinics have also begun to be influential in 




studies include evaluating the utility of PET [7-12], PET/CT [13-15], and PET/MRI [16-17]. 
Colorado State University (CSU) James L. Voss Veterinary Teaching Hospital was one of the 
first universities to install a dedicated veterinary PET/CT in 2009.  The first PET/CT procedure 
completed at CSU was of a Boston Terrier on October 27, 2009. Since the installation of the 
PET/CT in 2009, more than two hundred scans on a variety of animals have been conducted 
utilizing PET, CT, or combined PET/CT. Dogs, cats, and sheep have been imaged at CSU. As 
PET/CT continues to be integrated into the medical community for its numerous benefits [1], it 
can only be assumed that the popularity of the imaging modality will continue to be adopted into 
the veterinary community as veterinarians become more familiar with the technology and its 
application [5-6]. 
Positron Emission Tomography (PET) [7] 
 PET is a nuclear imaging modality that provides detailed information about how a 
patient’s tissues and organs are functioning physiologically and metabolically. PET is commonly 
utilized for disease detection, diagnosis, staging, surgical and/or radiation treatment planning, 
and treatment assessment. In human medicine, PET is primarily used for oncology but PET is 
also becoming routinely applied in neurologic and cardiac studies [3]. 
The PET imaging process relies upon radiopharmaceuticals to decay by positron 
emission. Positron decay only occurs in radionuclides that have an abundance of protons in the 
nucleus and at least 1.02 MeV of excess energy. When a positron emitter decays, one of the 
protons in the nucleus is converted into a neutron, positron, and a neutrino; the positron and the 
neutrino are emitted out of the nucleus with a specific amount of energy. The reason an energy 




positron, and neutrino requires energy to create mass. An example of positron decay of copper-
64 to nickel-64 is shown below. 
    
         
          
Neutrinos have no net charge and nearly no mass and due to these qualities neutrinos have an 
exceptionally low probability of interaction with matter and are considered insignificant in 
radiation protection [37].  The ejected positron will travel a short distance (on the order of a few 
millimeters) from the original nucleus and will interact with an electron. The positron and 
electron will annihilate each other during the interaction. The masses of both the positron and the 
electron are converted into electromagnetic energy and produce two 511 keV gamma rays 
(photons). The gamma rays are formed simultaneously and are oriented 180 degrees from each 
other. As mentioned earlier, PET relies upon positron emission to generate a pair of 511 keV 
photons to image the patient. Figure 2 provides a simple visual example of positron decay and 





Figure 2: Positron Decay and Annihilation – Simple illustration of a positron and electron 
annihilating, producing two 511 keV photons approximately 180° in opposite directions. 
              A limiting factor in PET/CT is the amount of radiation exposure to the patients and to 
the occupational workers. This study focuses on comparing the doses received by occupational 
workers during routine procedures from the radiopharmaceutical 
64
Cu-ATSM with the common 
radiopharmaceutical Fludeoxyglucose (FDG).
 
There have been multiple studies that assess the 
occupational dose received by workers in the human medical field utilizing a variety of imaging 
radiopharmaceuticals [19-30] but the literature on occupational doses to veterinary personnel is 
extremely limited [2]. Veterinary nuclear medicine offers challenges that are not encountered in 
human nuclear medicine. For example, it is standard veterinary procedure to place patients under 
anesthesia to ensure the patient remains stationary for optimal image acquisition. Patients must 
be closely monitored when under anesthesia. The amount of time anesthesiologists and nuclear 
technicians spend in close proximity to the patient is increased resulting in increased 
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occupational exposure.  Placing veterinary patients under anesthesia is a key difference between 
human and veterinary nuclear medicine. Human nuclear medicine patients generally can be told 
to remain stationary during procedures, eliminating the need for an anesthesiologist. Human 
patients can also be placed in isolation during the imaging procedure, reducing patient contact 
with the workers involved.  Anesthetized patients require additional workers to be present during 
the procedure as well as requiring direct contact with the patient. Thus PET/CT procedures that 
anesthetize patients have the ability to exposure more workers to a higher amount of radiation 
exposure. Additional differences between veterinary and humane nuclear medicine procedures 
include, but are not limited to, the quantity of injected radioactivity and patient size variance. 
The typical radiopharmaceutical doses for humans ranges between 370-740 MBq [31] with up to 
thirty patients being seen on a single day [32]. In this study, the injected activity ranged from 
98.6-218.3 MBq (approximately 5 MBq kg
-1
), with seven procedures performed over 
approximately one year or an average of 0.02 patients per day. 
Radiation Interactions in Matter 
 In this study the word “radiation” is defined as energy emission, in the form of either a 
particle or a wave that will ionize electrons in a material. Radiation can interact with matter by 
causing excitations (raising an electron to a higher energy level) or by ionizations (creating ion 
pairs by separating electrons from the nucleus). When radiation interacts with a material by 
either of these methods, the radiation will lose a portion or all of its associated energy. Energy is 
lost by the radiation and is deposited in the material. The amount of energy deposited depends on 
the type of interaction. PET scans are based on the detection of  0.511 MeV annihilation photons, 




mechanism) [33]. Both of these mechanisms are photointeractions because the mechanisms are 
specific only to electromagnetic radiation (photons). 
 When radiation is deposited in living tissues, the primary biological effect observed is 
DNA damage. Photons do not typically damage DNA directly, but photons damage DNA 
indirectly by interacting with the medium surrounding the DNA (cellular fluids). Interactions 
with cellular fluids create charged particles which can then lead to free radical formation. Free 
radicals may cause single stand breaks (SSB) or double stand breaks (DSB) in the DNA. Low 
level exposures may cause SSB, and larger exposures may result in multiple simultaneous SSB 
in the same strand of DNA leading to a DSB. SSB can be repaired efficiently while DSB are 
difficult to repair [34].  
Basic Radiologic Principals 
 Absorbed Dose, D, is the average amount of energy absorbed per unit mass of a material. 
The basic concept of dose assessment is to determine the amount of Absorbed Dose in specific 
organs or tissues, apply radiation weighing factors (wR) to take into account the different types of 
radiation (Equivalent Dose, HT), then apply tissue weighing factors (wT) for different 
organ/tissue sensitivities (Effective Dose, HE).  Radiation protection quantities like Equivalent or 
Effective Dose are not directly measureable. However, operational quantities can be measured 
and these quantities can be used to determine equivalent or effective dose. For routine 
monitoring, operational quantity values are an accurate and precise assessment of effective dose 
[33].  
 During routine area monitoring, the operational quantity used to assess effective dose is 
Ambient Dose Equivalent, H*(d), where d is depth in millimeters. Since the primary radiation of 




instruments were calibrated to properly measure the Ambient Dose Equivalent of deeply 
penetrating radiation, H*(10). However, many instruments do not measure Ambient Absorbed 
Dose but instead measure the rate of exposure.  Exposure is a measure of the quantity of x-ray or 
gamma radiation that produces a number of ions in a volume of air.  The unit of exposure is the 




 or 1 sC cm
-3
 at STP (T = 273 K, P = 760 mm 




) [33].  
 Another operational quantity is Personal Dose Equivalent, HP(d), where d is depth in 
millimeters. The difference between Personal Dose Equivalent and Ambient Dose Equivalent is 
that ambient dose is measured in free air while personal dose is measured incident on the body. 
The reason for this is that a radiation field is strongly influenced by backscatter and absorption of 
radiation by the body. Therefore Personal Dose Equivalent is suited for monitoring individuals.  
Since the radiation of concern from 
64
Cu is deeply penetrating, worker’s dosimeters were 
calibrated to a depth of ten millimeters, HP(10). 
 The SI unit for Absorbed Dose is the Gray (Gy). It is defined as the absorption of 1 J kg
-1
. 
The Sievert (Sv) is the unit used to express Equivalent Dose and Effective Dose. A measure of a 
quantity of radioactivity of a material is the Becquerel (Bq). A Becquerel is defined by the 
quantity of radioactive material in which one atom is decayed per second or 1 dps. The units of 
Gy, Sv, and Bq are part of the SI unit system and have not been completely adopted in the US 
[35]. The US and SI units measure the same quantities but are expressed using differing units. 
The table below provides a summary of the dosimetric and radiometric units [36]. 
Table 1: Units of Radioactive Materials and Dose 
Measure Unit Abbreviation Conversion(s) 
Activity (A) Becquerel Bq 1 Bq = 2.7 × 10
-11








1 Bq = 1 dps  
1 Ci = 37 GBq 







1 Gy = J kg
-1
  
1 Gy = 100 rad 
1 rad = 0.01 Gy 
Equivalent Dose (HT) and 





1 Sv = 100 rem 
1 rem = 0.01 Sv 
Exposure (X) Roentgen R 





1 R = 8.76 × 10
-3
 Gy (air) 
1 R = 9.5 × 10
-3
 Gy (soft tissue) 
 
Positron Emission Tomography 
 PET relies upon the detection of a pair of photons. This is known as coincidence 
detection, meaning that any single interaction event is ignored unless there is another interaction 
on the opposite side of the detector. After the detection of a single photon, a period of up to 495 
picoseconds may elapse before the detection of the second photon will be considered 
coincidence and not random [38]. Coincidence detection is a way to discriminate all other 
radiation processes except for the photons created during the annihilation process. When 
coincidence photons are detected in the scintillating crystals, the radiation is absorbed in the 
LYSO crystals. The photons cause the scintillating crystals to produce flashes of light, with the 
intensity of light being proportional to the amount of radiation absorbed. Each crystal is 
connected to a Photomultiplier Tube (PMT). A PMT converts the light in the crystals into 
electrons using a photocathode. These generated electrons are then accelerated across multiple 
potential differences, creating a cascade of electrons thus amplifying and generating a signal. 





Figure 3: Scintillating Process - Incident radiation interacts with the crystal causing the 
formation of an electron-hole pair, (a).  The hole then migrates to the activation site and ionizes 
it, (b). The electron is trapped in an ionized activation site, (c). The electron relaxes into the 
activation ground state by emitting light, which is then converted into an electric signal by the 
PMT, (d) [45]. 
The signal generated by the PMT is then passed through a preamplifier, energy level 
discriminators and on to coincidence circuitry for appropriate processing. The straight line 
between the two annihilation photons is known as the line of response and the PET scanner 
utilizes the fact that the origin of annihilation photons occurs on the line of response. Detectors 
with Truflight technology, also known as time-of flight technology, measure the difference in 
time (as the photons travel at the speed of light) between the detection of the coincidence 
photons, and use this information to attain more precision in the location of the annihilation 
event. There are several ways to reconstruct an image from numerous lines of response, but the 
end result is that the statistics collected from the analysis of all coincidence events can be used to 






Figure 4: PET Imaging – Individual pairs of annihilation photons ether scatter or generate a 
signal. The summation of signals from many annihilation pairs pieced together can be used to 
generate a map of a body. 
Radionuclide Details 
 Radiopharmaceuticals are formed by taking a positron emitting radionuclide and binding 
it to a biologically relevant compound such as glucose, water, or ammonia. This compound is 
known as a tracer and the tracer will determine the biological distribution of the 
radiopharmaceutical. A short half-life is a desirable trait of radionuclides that are used in PET, to 
study biological processes that have relatively rapid turnover.  In general, having a short-lived 
radiopharmaceutical allows better quality images to be obtained quickly. The predominant 
radionuclide used in PET is 
18




glucose compound to become Fludeoxyglucose (FDG). FDG is currently the only PET 
radiopharmaceutical approved by the FDA for cancer imaging. Because of the acceptance and 
use of FDG in the medical field, FDG has become the ideal standard to compare potential 
imaging radiopharmaceuticals against. 
The radionuclide used for this study was 
64
Cu, which has a half-life of 12.7 hours. One of 
the distinct advantages of 
64
Cu is that the longer half-life allows the nuclide to be produced off-
site and shipped to the clinic but the radionuclide is still short enough to be useful for diagnostic 
imaging. 
64
Cu has a complex decay scheme compared to other positron emitters used for 
imaging, such as 
18
F. Approximately 97% of the 
18
F decays are from positron emission while just 
fewer than 18% of decays from 
64




Cu Decay Scheme 
 
64
Cu-ATSM is a complex of copper(II) paired with the tracer diacetyl-bis (N4-
methylthiosemicarbazone), as shown in Figure 4.  One of the unique aspects of 
64
Cu-ATSM is its 
hypoxia-selectivity.  Hypoxia is a key element to consider for tumor diagnosis and radiotherapy 




vasculature in the tissue. The lack of oxygen causes the cells to become resistant to specific types 
of radiation, such as β
-
 or γ radiation, that are commonly used for therapy [34]. However, despite 
the exhaustive amount of work describing in vitro chemical, biological, and spectroscopic studies 
as well as in vivo research using PET imaging and pO2-dependence of cellular uptake, the exact 
mechanism of localization and trapping of 
64
Cu-ATSM in cells is still uncertain [39].  
 
Figure 6: Copper (II) (diacetyl-bis (N4-methylthiosemicarbazone)) Structure 
 
 There are two well known theories for describing the trapping mechanism of 64Cu-ATSM 
in a cell. The first was proposed in 1997 by Fujibayashi et al [40]. Evidence supported by 
experimentation showed that Cu-ATSM accumulated in hypoxic myocardium by means of 
biological reduction by  nicotinamide adenine dinucleotide dependent enzymes. The reduction of 
Cu-ATSM only occurs in hypoxic cells and the Cu-ATSM becomes irreversibly trapped upon 
intracellular reduction. The reduction mechanism involves an electron transfer from ubiquinone 
oxidoreductase using nicotinamide adenine dinucleotide as a two-electron donor. Since the 
enzymes required for this reduction process are located only in the mitochondria of the cells, it 




method of trapping was furthered by Obata et al in 2001. This study showed that in subcellular 
fractions of Erhlich ascites tumor cells, it was not the enzymes from the mitochondria but those 
from the microsome/cytosol fraction that mediated the reduction of Cu-ATSM. It was also 
discovered that the reduction mechanism was heat sensitive and could be enhanced by adding 
both nicotinamide adenine dinucleotide and reduced nicotinamide adenine dinucleotide 
phosphate to the cells of interest and that alone neither nicotinamide adenine dinucleotide nor 
reduced nicotinamide adenine dinucleotide phosphate were capable of reducing Cu-ATSM 
unaccompanied by the compound [41]. However, these methods have been found to not be fully 
consistent with observed cellular uptake and washout studies [39]. 
 The second method was proposed by Dearling et al in 1998. It was postulated that the 
Cu-ATSM reduction is reversible and occurs in both normoxic and hypoxic cells. Since the 
reduction is reversible, the reduction creates an unstable anionic copper(I) complex during 
uptake. It is then suggested that this copper(I) complex then slowly disassociates in hypoxic 
cells, leading to the irreversible trapping of the copper(I) ion. If the cell was normoxic, the 
normal levels of oxygen would oxidize the copper(I) complex to produce neutral copper ions, 
which would then diffuse back out of the cell [42-44]. 
Objectives of Study 
 
 The purpose of this study was to determine, per patient, the occupational dose delivered 
to the veterinary personnel working with 
64
Cu-ATSM imaging agent for PET scans at the 
Colorado State University’s James L. Voss Veterinary Teaching Hospital. The study was 
conducted by providing veterinary personnel two Electronic Personal Dosimeters (EPDs) to be 
worn on the chest and waist during each imaging procedure. EPDs measure real-time radiation 




participating member of the study. The VTH workers involved in this study were the following: 
nuclear medicine technologists, anesthesiologists, and radiobiologists. The dose measured by 
each of the distributed EPDs was recorded for each of the imaging procedures. Seven canine 
patients of varying breeds and sizes over a period of approximately one year were imaged. Only 
the first four patients enrolled into the study were tumor bearing dogs. The remaining three 
canines enrolled in the study were purpose breed research dogs. Table 2 provides a summary of 
the patient tumor information. 
Table 2: Patient Tumor Information 
Patient # Tumor Classification Tumor Grade 
1 Myxosarcoma Not Available  
2 Soft Tissue Sarcoma Grade 3 
3 Osteosarcoma Grade 3 
4 Soft Tissue Sarcoma Grade 2 
 
To reiterate, differences exist in human and veterinary PET/CT procedures that leads to 
an increased potential for veterinary workers to be exposed to higher levels of radiation. The 
hypothesis of this study is that the doses delivered on a per patient basis to the medical staff of 
the VTH from PET procedures utilizing 
64
Cu-ATSM would be comparable to the levels of 
exposure delivered to human medicine workers from PET procedures using Fluorine-18 (
18
F) 
radiopharmaceuticals, specifically FDG. The second part of the hypothesis is that the PET 
veterinary occupational exposures from 
64
Cu-ATSM procedures will be equivalent to the 








Colorado State University Positron Emission Tomography 
The PET/CT scanner at the CSU VTH is a Philips Healthcare Gemini Truflight Big Bore 
with separate housings for the PET and CT gantries [38] (Figure 5). The scanner consists of a 
ring (made of 44 individual rings) of scintillation crystals that encircle the patient’s body, 
covering 18 cm of the patient’s body at any single moment. There are a total of 28,336 lutetium 
yttrium oxyorthosilicate (LYSO) scintillating crystals in the detector array [38]. 
 
Figure 7: Philips Gemini Truflight Big Bore PET/CT 
Prior to a PET scan, an appropriate radiopharmaceutical must be injected intravenously 
and given time to distribute throughout the body. The radiopharmaceutical is absorbed by cells 
while being distributed throughout the body. The absorption of the radiopharmaceutical is 
described as uptake, which varies based upon the metabolic activities of the cells and the 
biological properties of the radiopharmaceutical. As described earlier, PET is commonly paired 




precise localization and quantification of radiopharmaceutical uptake.  At the VTH, PET is 
combined with CT to estimate/correct for self-attenuation/absorption and helps improve PET 
image quality. 
Electronic Personal Dosimeters 
EPD’s were MPG Instruments Mirion Technology model DMC 2000S (San Ramon, CA). The 
EPD’s utilize a single solid state semiconductor detector for detecting gamma radiation. The 
DMC 2000S is compliant to IEC 1283 and ANSI 4220A standards. The DMC 2000S 
instantaneously measures, records, and displays the amount of radiation dose from 10 µSv to 10 
Sv or radiation dose rates from 0.01 mSv hr
-1
 to 10 Sv hr
-1
. The DMC 2000S is only sensitive to 
x-ray or gamma radiation with energies between 50 keV to 6 MeV and the accuracy of the model 
is within ±10%. The EPDs were calibrated at Palo Verde Power Generating Station July of 2012 
and again Oct. of 2013. During the study, the EPDs were operating in autonomous mode, with 
the doses being manually read and recorded in the units of millirem (mrem). The radiation dose 














Human Use Protocol 
 The measurement of worker doses was approved by the CSU Institutional Review Board 
as a minimal risk study. The human use protocol was approved on July 18
th
, 2012. The human 
use protocol Notice of Approval is attached as Appendix A.  
Animal Use Protocol 
The proper care and treatment of the animals used in this study was approved by the CSU 
Institutional Review Board as a minimal risk study. The animal use protocol Notice of Approval 
is attached as Appendix B.   
Electronic Personal Dosimeters 
The study was task oriented to elucidate doses to generic workers performing a task in a 
position, so as to eliminate variability in the study. At the beginning of each procedure, each 
worker was given two EPDs, one worn on the chest and the other at the waist. A control EPD 
was placed in the Animal Cancer Center (ACC) room 148 to monitor background radiation 
during each of the procedures. The difference in height and weight of each participating worker 
was not included in the study. Each worker returned their EPDs to ACC 148 to be stored with the 
control EPD upon completion of their task. Figure 8 demonstrates the positioning of the EPDs 
during a procedure. The workers wore one of the distributed EPDs in the left front shirt pocket 
and the other in their pants pockets or in their belt like a pager. Exact EPD placement on the 




Each job position was designated by an abbreviation. Table 3 gives a description of each 
of the job positions, the corresponding EPDs, along with the duties each worker was expected to 
perform.  
Table 3: Job Descriptions Corresponding to Assigned EPDs 




Cu with ATSM and prepare 
required amount of activity to be injected 
TRANS 
Research Associate in Computed 
Tomography (CT) and Magnetic 
Resonance Imaging (MRI) 
Transport the radiopharmaceutical from the 
hot lab to the PET/CT suite to be injected 
ANEST Anesthesiologist 
Anesthetize the patients, to include 
catheterization, intubation/extubation, 
general monitoring and recovery of the 
patients. 
NUC MED 
Research Associate in Computed 
Tomography (CT) and Magnetic 
Resonance Imaging (MRI) 
Primary PET/CT technician. Performs, 
supervises, oversees safety, provides clinical 
instruction in CT, PET/CT, and MRI studies 
SURGEON Clinical DVM 









Patient Information Summary 
 Seven canines were enrolled to be imaged with 
64
Cu-ATSM during this study. The 
Clinical Trials team of the Flint Animal Cancer Center was responsible for the recruitment of the 
four tumor bearing canine patients (patients 1-4). The criterion for selecting patients was that the 
patient must be in sufficient health to be able to tolerate a long anesthetic process without 
needing direct medical care. Other criteria included the diagnosis of a soft tissue sarcoma ≥ 4 cm 
in diameter amenable to biopsy. All the owners of possible patients were informed of the study 
and offered enrollment. The remaining three dogs enrolled in the study were imaged as part of a 
study to evaluate the potential use of penicillamine to reduce the uptake of 
64
Cu-ATSM by the 
liver. 
The seven patients were imaged between the 15
th
 of January 2013 and the 28
th
 of October 
2013. Each dog was imaged with 
64
Cu-ATSM. A summary of the patients is shown below in 
Table 4. 
Table 4: Patient Summary 
Patient Breed Injected Activity 
[MBq] 
Mass [kg] Injected Activity / Mass 
[MBq / kg] 
1 Mixed 206.1 42.0 4.9 
2 Vizsla 98.6 20.0 6.0 
3 Labrador 218.3 36.5 4.9 
4 Great Dane 215.5 55.1 3.9 
5 Hound 108.1 28.0 6.7 
6 Hound 159.1 27.0 5.9 
7 Hound 170.0 27.0 6.3 
Mean ± SD - 179.4 ± 42.1 33.7 ± 11.9 5.5 ± 1.0 





Figure 9 is a picture of the largest patient enrolled in the study, Molly, a Great Dane. Molly was 
the 4
th
 patient to be enrolled in the study and carried a Grade 2 soft tissue sarcoma.  
 
Figure 9: Largest Patient in Study: 55.1 kg Great Dane 
 The amount of injected activity was fairly consistent on a per mass basis, approximately 
5 MBq kg
-1
. Figure 10 shows the relationship between injected activity and patient mass.   
 




Animal Imaging Protocol Summary 
 Approximately fifty mCi (or 1.85 MBq) of 
64
Cu produced by University of Wisconsin 
was received at the VTH the morning of each PET scan (the quantity of radioactivity varied 
based on the weight of the dog being imaged). The 
64
Cu was delivered in a syringe housed in a 
lead containment vessel, known as a “Pig” (Figure 11).  
 
Figure 11: Lead Pig Housing – Left: Extracting the 64Cu from the lead pig to determine the 
activity of the shipment. Right: A picture of the lead pig inside of the shipping container. 
 After the arrival of the 
64
Cu at the VTH, the dog was taken to anesthesia in preparation 
for the procedure. The dog was placed under anesthesia in Room C108. Once the patient was 
under anesthesia, urinary and intravenous (IV) catheters are put into place. The dog was then 
transported from the anesthesia suite to the PET/CT suite (Room H106) and then placed upon the 
table of the PET/CT. The dog was then positioned on the table for the imaging procedure 





Figure 12: Placement of Urinary and Intravenous Catheters – Left: Intravenous catheters placed 
for the purpose of the injection of the radiopharmaceutical and anesthesia. Right: Placing tubes 
to assist the dog with breathing while under anesthesia. 
 
Figure 13: Patient Placement on PET/CT Gurney 
Positioning the canine patient may include adjusting ECG leads or covering the patient 





Figure 14: Patient Adjustment Before PET/CT Scans 
While the dog was being prepared for the PET/CT procedure, the 
64
Cu was labeled with 
diacetyl-bis(N4-methylthiosemicarbazone (ATSM). The labeling was performed in the VTH 
radiopharmaceutical lab located in room 159a (Figure 15).  
 




Once the radiopharmaceutical was labeled, it was then placed in a lead lined container, 
transported to the PET/CT suite, and injected into the patient as depicted in the figures below. 
 
Figure 16: Lead Pig Used to by Technologist to Transport Radiopharmaceuticals 
After the injection, the residual dose was transported back to the laboratory used to 
prepare the radiopharmaceutical to ascertain the net injected activity. Dynamic and/or static PET 
and CT scans were then performed to collect appropriate diagnostic imaging data. 
Once the imaging procedure was complete, all catheters were removed and the canine 




located in ACC 162. The dog was then woken up from under anesthesia and allowed to recover 
(Figure 17). 
 
Figure 17: Canine Patient Recovery 
The patient was held in a shielded kennel area until the maximum skin surface reading 
was ≤ 2 mR/hr (17.5 µGy/hr). The patient was monitored and walked to allow voiding of bladder 
and bowels. The patient was walked in a designated area that is closed off by a chain link fence. 
Appendix D shows a sample of a data collection sheet used in the study and Appendix E 
describes the floor plan of the VTH. In the protocol described above, the potential for radiation 
exposure to occupational workers exists in the following tasks: 
 Dose Package Receipt 
 Radiopharmaceutical Preparation 





 Room Entry During PET/CT Scans to Check Patient 
 Moving Patient from Table to Gurney  
 Patient Transportation to Nuclear Ward 























Data Analysis- EPDs 
 Data was collected for five different workers during the seven imaging procedures.  A 
detailed description of the workers’ positions is in Table 2. All five workers did not participate in 
each imaging procedure. Also, additional data was collected only for the radiobiologist labeling 
64
Cu with ATSM because 
64
Cu-ATSM was also purchased for other research purposes. Table 5 
summarizes the readings from the EPDs assigned to the workers. The doses were recorded in 
millirem (mrem) but are presented here in microSieverts (µSv).  


























3 2 11 11 3 3 7 10 0 0 
Procedure 
2 
12 12 2 2 3 2 2 2 0 0 
Procedure 
3 
1 5 0 1 1.1 1.2 3 4 0 0 
Additional
1
 - - - - 7 5 - - - - 
Procedure 
4 
3 4 5 8 17 14 0 1 0 0 
Procedure 
5 
2 4 8 14 7 5 - - 0 0 
Procedure 
6 
1 3 2 3 8 6 - - 1 0 
Procedure 
7 
2 2 4 7 5 5 - - 0 0 
Mean            
± SD 
3.4     
± 3.9 
4.6  
 ± 3.5 
4.6   
± 3.8 
6.6  
 ± 4.9 
7.7  
 ± 4.6 
6.2  
 ± 4.2 
3.0          
± 2.9 
4.3           
± 4.0 
0.1          
± 0.4 
0.0       
± 0.0 
Range 1 to 
12 



















 A statistical analysis was conducted on several factors that might impact the dose 
received by the workers during a procedure. The following factors were examined: job duty, 
                                                          
1
  An additional order of 
64





location of EPD, duration of exposure in minutes, and injected activity in megabecquerels. The 
mass of patients was not included in the analysis because the injected activity per unit mass was 
constant throughout the study. It is known that the mass of the patient will alter the attenuation of 
radiation, but it was beyond the scope of this study to examine the attenuation due to the mass of 
the patient. Since the EPDs assigned to the transportation of the radiopharmaceutical recorded 
negligible amounts of exposure, those EPDs were excluded from analysis. Table 6 summarizes 
the factors for the EPDs worn on the chest. The values listed in Table 6 are identical to the 
factors for the EPDs worn on the waist, meaning that the only difference in the factors is the 
location of the EPD. 
Table 6: Radiation Dose Affecting Factors for EPDs Located on the Chest 
  Anest Nuc Med Prep Surgeon 
Procedure Activity [MBq] Duration [min] Duration [min] Duration [min] 
Duration 
[min] 
1 206.1 264 263 79 107 
2 98.6 245 245 141 87 
3 218.3 280 280 154 77 
Additional - - - 70 - 
4 215.5 281 281 113 24 
5 188.1 400 400 113 - 
6 159.1 394 392 122 - 
7 170.0 309 308 97 - 
Mean ± SD 179.4 ± 42.1 310.4 ± 62.2 309. 9 ± 61.9 111.1 ± 28.7 73.8 ± 35.4 
Range 98.6 to 218.3 245 to 400 245 to 400 70 to 154 24 to 107 
 
Only two factors were statistically significant (p-value ≤ 0.05) based on linear regression 




exposure time has already been established as a core principal of external radiation safety [33], 
the relationship between dose and the location of EPD was examined further.  
 The recorded doses of the EPDs worn on the chest were plotted against the doses 
recorded on the EPDs worn on the waist as shown in Figures 18 to 21. 
 
Figure 18: Chest vs. Waist EPD Analysis of Radiobiologist Preparing the Radiopharmaceutical 
(Prep) 
 





Figure 20: Chest vs. Waist EPD Analysis of Nuclear Medicine Technician (Nuc Med) 
 








 Table 7: Summary of EPD Linear Regression Analysis 
 
Table 7 provides a summary of numerical analysis presented in Figures 18 – 21. The 
anesthesiologist (Anest), the nuclear medicine technician (Nuc Med), and the surgeon plots all 
have a slope ≥ 1, meaning that the chest EPD recorded a higher dose than the waist EPD. The 
EPDs assigned to the radiobiologist (Prep), produced the reverse situation, with a slope ≤ 1 and 
the waist EPDs recording a higher dose. To avoid confusion, the location of the EPD does not 
change the radiation dose to the worker, only the accuracy of the measurement. The location of 
the EPD alters the accuracy of the measurement by affecting the geometry of the system. Placing 
an EPD at different locations on the torso will change the distance between the radioactive 
source (the patient) and the EPD. Since the quantity of interest is the maximum whole body dose, 
the EPD should be placed on the part of the torso closest to the radioactive source to achieve an 
accurate measurement, as Figures 18 - 21 illustrate. 
It was assumed the radiation dose was zero upon energizing each EPD used in the study and 
background radiation was constant during all procedures. By assuming each EPD is absent of 
any radiation dose upon energizing, the linear regressions in Figures 15 - 18 are forced to pass 
directly through the origin. This creates a simple linear equation that describes the radiation dose 
to EPDs worn on the chest as a function of radiation dose of EPDs worn on the waist. 
 
 
 Prep Anest Nuc Med Surgeon 
R
2
 Value 0.9134 0.7176 0.8292 0.9649 
P Value 0.0002 0.0019 0.0012 0.0169 




Data Analysis- Comparison to Human Studies 
 There is a dearth of literature on worker doses from the use of 
64
Cu-ATSM for PET 
studies. There have been no reported studies that assess the occupational exposure to medical 
staff from human 
64
Cu-ATSM procedures but there have been studies that estimate the absorbed 
radiation dose to human patients. A concise summary of these studies are shown in Table 8. All 
doses reported in Table 8 are mGy per MBq. 
Table 8: Summary of Absorbed Radiation Doses from 
64
Cu-ATSM to Human Patients 
 Lead Author 
Organ Laforest [11] Lewis [48] 
Liver 0.390 0.187 
Kidneys 0.088 0.064 
Spleen 0.047 - 
Gallbladder 0.068 - 
Adrenals 0.032 - 
Heart Wall 0.029 - 
Pancreas 0.056 - 
Upper Large Intestine 0.022 - 
Lungs 0.021 - 
Stomach 0.021 - 
Small Intestine - 0.109 
Urinary Bladder - 0.019 
Total Body 0.026 0.026 
 
 Although some dosimetric studies with 64Cu-ATSM has been published, a comparison 




directly from the injected radiopharmaceutical and tends to focus more an individual organs 
while occupational doses are external to the body and focus on whole body exposure.  Internal 
and external dosimetry also rely on drastically different mathematical models to describe the 
exposure. Since no occupational studies have been conducted with 
64
Cu-ATSM, a comparison 
with another PET radiopharmaceutical was made. Fludeoxyglucose (FDG) is the predominant 
PET imaging agent and is currently the only radiopharmaceutical certified by the FDA. In 
addition to FDG being the “golden Standard” of PET, multiple studies have been published 
examining occupational exposure to workers from FDG PET/CT scans in both human and 
veterinary medicine. The radionuclide used in FDG is 
18




Cu are used as 
PET imaging agents, comparing the two radiopharmaceuticals provides a valid perspective on 
the occupational exposures from 
64
Cu-ATSM. The comparison of two different isotopes is 
reasonable in ascertaining the worker doses, as PET emissions are uniformly 0.511 MeV gamma 
rays. Table 9 shows a concise summary of the doses to workers in human medicine from various 
studies. All values reported in Table 9 are study averages. 
Table 9: Radiation Dose to Workers from F18-FDG PET in Human Literature 





Benatar [20] - 18 EPD 
Biran [47] 7.2 19.5 TLD and EPD 
Carson [21] 5.1 13.6 EPD 
Chiesa [22] 5.9 11.8 Geiger Muller PD 
Dalianis [23] 3.3 8.6 TLD and EPD 
Demir [46] 6.3 12.2 TLD and EPD 
Guillet [24] 3.2 9.4 TLD and EPD 




McCormick [27] 14.0 - TLD 
McElroy [19] 10.0 18.6 EPD 
Roberts [28] 4.5 15 TLD 
Robinson [29] 4.1 11.0 TLD 
Seierstad [30] 8.8 25.0 EPD and TLD 
Mean ± SD 6.4 ± 3.2 - - 
95% Confidence 
Interval 
4.4 to 8.4 - - 
 
 Making a comparison between the mean radiation doses of the veterinary workers 
reported in Table 5 and the confidence interval reported in Table 9, three of the eight mean 
radiation doses are outside of the confidence interval on the low side with the rest of the means 
falling inside of the interval (Table 10, all values in µSv).  
Table 10: Comparison of 
64
Cu-ATSM Occupational Veterinary Worker Doses Compared to 95% 
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Inside Inside Inside Inside 
Outside 
3.0 < 4.4 
 
Outside 
4.3 < 4.4 
 
 
Note that the studies summarized in Table 9 are all worker doses from human patients and the 
average injected activity of FDG (not 
64
Cu-ATSM as in this study) is typically on the order of 
approximately 370 - 740 MBq, compared to the average injected activity of 179 MBq of 
64
Cu-
ATSM for canine patients. It is surprising that the majority of the mean radiation doses fall 




the FDG studies is a factor of two to four times more than the amount of radioactive copper 
involved in the canine study. The majority of worker mean radiation doses from veterinary use of  
64
Cu-ATSM are within the 95% confidence interval of  human occupational exposures from 
FDG, one may postulate that on average, veterinary procedures using 
64
Cu-ATSM deliver a 
worker radiation dose comparable to that received from workers attending to human FDG 
procedures. 
Data Analysis- Comparison to Veterinary Studies 
 No studies on 
64
Cu-ATSM occupational exposure to veterinary workers were located in 
the literature. Only a single study by Martinez et al was found that discusses veterinary 
occupational exposures from FDG [2]. Martinez created a mathematical model, for both canine 
and feline patients, to estimate radiation dose to specified workers. The results of Martinez’s 
study are summarized in Table 11. The values reported in Table 11 are predictions from her 
model and are reported in µSv from the average amount of injected activity (155.8 MBq) used 
for the canine patients.  
Table 11: Summary of Veterinary Occupational Exposure from Canine FDG Procedures from 
the Mathematical Model Developed by Martinez [2] 
 Tech 1 Tech 2 Tech 3 Average 
Tech 
Anesthesia Observer  
Chest 14.8 12.2 9.5 12.2 6.9 4.3  
Waist 11.2 8.6 6.0 8.6 3.3 0.7  
 
Different workers were monitored in the veterinary FDG occupational exposure study 
compared to our 
64
Cu-ATSM study. FDG is produced and shipped ready for injection, 
eliminating the need for preparing the radiopharmaceutical. In addition, veterinary surgeons were 




tasks (Tech 1, Tech 2, Tech 3) allowing individual monitoring of  each worker performing the 
duty of the nuclear technologist. The average dose of all three nuclear technicians is included in 
Table 11. The 
64
Cu-ATSM study did not include an observer and was omitted.  
 A comparison of the mean veterinary FDG nuclear medicine technologist and 
anesthesiologist values and the 95% confidence interval for the 
64
Cu-ATSM nuclear medicine 
technologist and anesthesiologist are shown here in Table 12. The average doses to the nuclear 
medicine technologist in the FDG study exceed the 95% confidence interval for both the chest 
and waist while the anesthesiologist is inside the interval for both positions of the EPD. Since 
half of the values are outside of the confidence interval on the high side, the results imply that 
occupational radiation doses from veterinary FDG procedures are higher than veterinary 
64
Cu-
ATSM procedures.  
Table 12: Comparison of Veterinary Occupational Exposures of FDG and 
64
Cu-ATSM for 
















FDG Means 3.3 6.9 8.6 12.2 
95% 
64
Cu-ATSM Confidence Interval 
for Nuclear Medicine Tech Chest 
(3.0 - 10.2) 
- - - 
Outside 
12.2 > 10.2 
95% 
64
Cu-ATSM Confidence Interval 
for Nuclear Medicine Tech Waist 
(1.8 – 7.4) 
- - 
Outside 




Cu-ATSM Confidence Interval 
for Anesthesiologist Chest 
(2.0 – 7.2) 
- 
Inside 




Cu-ATSM Confidence Interval 
for Anesthesiologist Waist 
(0.5 – 6.3) 
Inside 
0.5 < 3.3 < 6.3 







 Anesthesia technicians rotate through clinical practices, providing anesthesia services for 
PET/CT patients. Several different anesthesiologists provided services for patients involved in 
the 
64
Cu-ATSM study and occasionally the anesthesiologist would change during a procedure so 
that a single imaging procedure might expose multiple anesthesia technicians (during the 
analysis, the assumption was made that only a single person was exposed to radiation per 
imaging procedure). Although each anesthesia technician provides essentially the same care to 
each patient, each technician has a personal style of care. Another dynamic factor that impacts 
the anesthesia process is the patient. Each patient responds differently to anesthesia and recovers 
differently from anesthesia. Differences in response and recovery to anesthesia greatly impact 
the amount of attention a patient needs. This variability extends to other non-anesthesia related 
work as others are required to help with patient’s positioning, set up, and recovery. The majority 
of radiation dose to the anesthesiologist is from recovering the patient but dose is also 
accumulated during room and patient position post injection.  
 The frequency of room entry is dependent upon the patient and is also a judgment call for 
the anesthesiologist. Recovery is the main opportunity for additional exposure to the 
anesthesiologist due to the time spent in close proximately to the patient. Recovery is usually a 
combined effort of both the anesthesiologist and nuclear medicine technician. It is difficult to 
predict how a patient will recover from anesthesia; a patient may wake up smoothly and require 
little assistance or may wake up quickly and require physical restraints and medical intervention. 
It was not uncommon during the imaging procedures for both the anesthesia and nuclear 




approximation for recovery is forty-five to sixty minutes for the patient to recover to the point 
where direct human supervision is not required. 
Variability- Surgeon 
 The activities of the veterinary surgeon also displayed a large degree of variance between 
procedures. Each tumor biopsy was performed by a different veterinary surgeon. Each patient 
biopsy was in a different location and the tumor types were not consistent throughout the study
2
. 
The location of the tumor seemed to be the largest factor impacting the duration of time the 
surgeon spent in close proximity to the patient. For example, the first patient of the study had a 
tumor filled with a mucus fluid that greatly expanded the size of the tumor. The biopsy process 
was difficult due to the fluid, and the surgeon remained in close contact with the patient for a 
longer duration of time than usual due to the complicated geometry of the tumor. The fluids of 
the tumor were also released during the biopsy adding additional radiation dose to the surgeon. 
Another example was imaging procedure 3, where the tumor was a large sarcoma on the side of 
the patient. Collecting the biopsy sample from patient 3 took a fraction of the time compared to 
patient 1 as there were no complicating factors involved. 
Variability- Procedures 
 Procedures 1 - 4 were conducted with cancer bearing dogs that were volunteered for the 
study.  Procedure 1 went according to the protocol with no abnormalities to report.  The nuclear 
medicine technician was the primary care giver during patient recovery.  
Procedure 2 went smoothly until patient recovery. Patient 2 was a Vizsla and this 
particular breed is known to have difficulty when recovering from anesthesia. The patient awoke 
and attempted to walk and stand.  The Vizsla patient then had to physically be restrained to keep 
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the patient lying down. The anesthesiologist physically held the patient for a period of time, 
greatly increasing the amount of radiation dose received.  
During procedure 3 there was a problem with the Philips PET/CT machine.  After the 
radiopharmaceutical was injected, software complications prevented the nuclear medicine 
technician from initializing the CT scans. This problem lasted for approximately ninety minutes. 
A Philips technician remotely operated the PET/CT machine to diagnose and correct the 
problem. Since 
64
Cu-ATSM has an unusually long radiological half-life of 12.7 hours, delaying 
the imaging process by 1.5 hours only reduced the injected activity to 92% of the original 
activity, and allowed for quality diagnostic images to be produced. The recovery of patient 3 was 
ideal. The patient was calm and relaxed during the recovery process from anesthesia.  
During procedure 4, the catheter used to inject the radiopharmaceutical was not 
successfully flushed or cleared from the catheter and a large amount of the injected activity (~ 
50%) pooled in the right forearm of the patient just beneath the epidermis. A diagnostic quality 
scan was achieved that was still clinically useful despite the difficulty. Both the nuclear medicine 
technician and the anesthesiologist were present during the recovery of patient 4 and as a result, 
a slightly higher radiation dose was recorded for both workers. It should also be noted that the 
radiobiologist changed how the radiopharmaceutical was prepared for this procedure. Usually all 
containers of radiation are kept behind lead shielding during the preparation process but during 
this procedure, several containers that contained small amounts of radioactivity were left 
unshielded and to the side of the lead shielding. This slight change decreased the 
radiopharmaceutical preparation time, and created less contamination in the laboratory but the 
radiobiologist did receive a higher dose than normal. Thus, the decrease in time did not offset the 




 Procedures 5 - 7 were healthy, purpose breed research hounds and each received an 
injection of penicillamine (20 mg kg
-1
 intravenously) during the procedure with the injection of 
the radiopharmaceutical. Penicillamine acts as a copper chelator in the liver. Since patients 5 – 7 
were healthy and free of cancer, no surgeon was required. The scans performed on patients 5-7 
were longer thus increasing the amount of time for a possible exposure for both the nuclear 
medicine technologist and anesthesiologist. During procedure 5, the patient had difficulty during 
recovery. The patient had a low temperature of 91.9°F at the completion of the PET/CT scan. 
After the patient was transported to the nuclear recovery ward, the anesthesia and nuclear 
medicine technician chose to warm the patient by rubbing the patient with a towel in an attempt 
to stimulate the tissues and increase body temperature. Because of the patient’s low temperature, 
recovering the patient from anesthesia took longer than usual (~ two hours). The anesthesiologist 
was also present during the “warming” process but the anesthesia tech spent much less time in 
close proximity to the patient.  
Procedure 6 was complicated because the 
64
Cu from University of Wisconsin arrived 
contaminated. Both the inside and outside of the lead transportation pig used to ship the 
radionuclide were contaminated with low levels of 
64
Cu. This delayed the imaging procedure by 
sixty minutes while decontamination took place. Surprisingly, despite the longer duration spent 
in the hot lab with the radionuclide, the radiobiologist did not receive a significantly higher dose. 
Also, the Philips PET/CT experienced another software problem that delayed the imaging 
process another hour.  The injected activity was corrected for decay prior to injection to account 
for the multiple delays.  
For procedure 7, the protocol was altered so that it spanned two days. On the first day of 




radiopharmaceutical. On the second day of the procedure 7, the dog was anesthetized and 
imaged.  
EPD Location Dependency 
 The location of the EPD has a large impact on the dose reading depending on the worker 
(see Figures 15-18 and Table 7). Wearing an EPD on the chest or waist does not change the 
amount of radiation a worker is exposed to, but only the accuracy of the measurement. The 
nuclear medicine technologist and surgeon EPD located on the chest recorded a radiation dose 
>30% more than the EPD located on the waist. The EPD located on the waist of the 
radiobiologist preparing the radiopharmaceutical recorded approximately 20% more radiation 
dose than the EPD worn on the chest. The location of the EPDs worn by the anesthesiologist did 
not affect the radiation dose and both EPDs recorded roughly the same dose. 
 Upon reflection the differences in the doses recorded by each worker can be explained. 
For the radiobiologist, the majority of the work performed was done in a fume hood with lead 
shielding and leaded glass. Thus the radioactive materials were generally closer to the waist EPD 
than the chest EPD during the preparation of the radiopharmaceutical leading to slightly higher 
readings on the waist EPD. The nuclear medicine technologist typically accumulated exposure 
when transporting the patient to the nuclear recovery ward and during the recovery of the patient.  
During both of these tasks, the nuclear medicine technologist was bending over the patient bring 
their chest close to the patient. This was especially seen during patient recovery when the patient 
was lying on the floor or being restrained by the nuclear medicine technologist. Thus since the 
chest EPD was generally the EPD closer to the patient, the chest EPD recorded more exposure. 
The surgeon spent time to the patient while the patient was still on the PET/CT table. Although 




view when collecting biopsy samples. By bending or crouching, the chest of the surgeon was 
always brought in close proximity to the patient and as expected the chest EPD always recorded 
a higher exposure. The anesthesiologist EPDs tended not to discriminate exposure based on 
location. This can be explained by the fact that the anesthesiologist typically did not spend 
durations of time in close proximity to the patient compared to the surgeon or nuclear medicine 
technologist. Thus the patient acted more like a point source instead of a volume source and the 
distribution of radiation was more equally distributed across the anesthesiologist’s body. 
Risk Assessment 
 There are several different standards that radiation exposures can be compared against 
and assessed. The doses recorded in this study were compared against the following: the quantity 
of radiation required to observe biological effects, background radiation across the nation and the 
world, and the radiological limits for the general public and radiation workers. The radiation 
doses received by the occupational workers in this study (maximum of 17 µSv in a single 
exposure or 61 µSv maximum cumulative exposure) were small compared to the threshold 
quantity of radiation needed to cause deterministic effects (roughly 1 – 2 Sv of gamma radiation) 
[34], but, assuming a linear no-threshold risk model, there is an slight increase in the probability 
of developing stochastic effects. In the field of radiation safety, the concept that any quantity of 
radiation will increase the risk of stochastic effects, such as cancer, is known as the Linear No-
Threshold Model [33]. Although other models exist, the Linear No-Threshold model is currently 
supported by the National Academy of Sciences, as well as the regulatory agencies of the USA. 
To quote the most current National Academy of Sciences Biological Effects of Ionizing 
Radiation (BEIR) VII report [48], 
“A comprehensive review of available biological and biophysical data supports a “linear-




lower doses without a threshold and that the smallest dose has the potential to cause a 
small increase in risk to humans.” 
 
It should be stated that despite widespread use, the Linear No-Threshold the model is not perfect. 
Evidence supports a linear relationship between effects and dose at high doses but little is known 
about the consequences of low level exposures of radiation (like those seen in this study). 
An example that quantifies the magnitude of the increased probability of stochastic 
effects due to radiation is shown in Figure 22. Based on an average lifespan of one hundred 
people, fifty-seven people are expected to be healthy (illustrated by the green circles), forty-two 
are expected to develop non-radiation induced cancers (depicted by the yellow squares), and an 
additional incidence of cancer is expected as a consequence of an exposure of 0.1 Sv (1640 times 
larger than the maximum cumulative dose from this study) above background (shown by the blue 
triangle) [48].  
 
Figure 22: Quantification of Radiation Induced Cancer from 0.1 Sv - Circles represent healthy 
people, squares represent naturally occurring cancer, and the triangle represents an expected 
cancer induced by radiation. All 100 persons are assumed to have a dose of 0.1 Sv. 
 The BEIR VII report also provides a more quantitative example. Assuming a population 
of 100,000 people (with an age distribution similar to that of the United States) was exposed to 
100 mSv (0.1 Sv) of gamma radiation, the corresponding cancer incidence and cancer related 





Table 13: BEIR VII Lifetime Attributed Risk Estimates from 0.1 Sv to a Population of 100,000 
 All Solid Cancers Leukemia 
 
Males Females Males Females 
Excess Cases (including non-
fatal cases) from Exposure to 
100 mSv 
800 (0.8%) 1,300 (1.3%) 100 (0.1%) 70 (0.07%) 
Number of Cases in the 
Absence of Exposure 
45,000 (45.5%) 36,900 (36.9%) 830 (0.83%) 590 (0.59%) 
Excess Deaths from Exposure 
to 100 mSv 
410 (0.41%) 610 (0.61%) 70 (0.07%) 50 (0.05%) 
Number of Deaths in the 
Absence of Exposure 
22,100 (22.1%) 17,500 (17.5%) 710 (0.71%) 530 (0.53%) 
 
 The maximum cumulative dose recorded during the study was 61 µSv. According to the 
International Commission on Radiation Protection, the probability of developing a fatal cancer 
increases 5% per Sv [49]. Thus the maximum cumulative exposure from the seven procedures 
completed corresponds to only a 0.0003% increase in the incidence of fatal cancer. Even if every 
imaging procedure completed in this study had been carried out by a single worker (276.6 µSv of 
total radiation dose for the seven procedures) and performed the study annually for a total of fifty 
years (receiving a total radiation dose of 13.83 mSv), the increased chance of developing a fatal 
cancer is only 0.0692%. 
 As mentioned, the results of this study can also be compared to average background 
radiation dose, both national and worldwide. Natural radiation exists all over the globe but the 
distribution of radioactivity is uneven. The geography and elevation of the location alter the 
levels of natural radioactivity because naturally occurring radioisotopes exist in the soil and 
radiation also enters our atmosphere as cosmic radiation. Table 14 summarizes levels of natural 




Table 14: Average Annual Background Radiation Dose 






 The maximum cumulative exposure from this study was 61.4 µSv. The length of the 
study was approximately one year (ten months) and the maximum cumulative exposure recorded 
during the study is only 1.12% of the national average annual background radiation dose and 
1.44% of the global average annual background radiation dose. A distribution of the average 
public radiation exposure is shown in Figures 23-24 [50-53]. 
  
Figure 23: United States Average Public Radiation Exposure Distribution – According to 
NCRP 1987, the annual exposure to the public nationally was 3.6 mSv and was increased to 





Figure 24: Global Average Public Radiation Exposure Distribution – According to UNSCEAR, 
the annual exposure to the public globally in 2000 was 2.81 mSv and was increased to 3.0 mSv 
by 2008. 
As Figures 23-24 depict, the global public exposure distribution has remained fairly constant 
over the last decade with only a minor increase to the medical exposure. However over the last 
two decades the American public exposure has drastically changed, especially in medical 
exposure. This is chiefly due to the annually increasing number of CT scans and nuclear 
medicine procedures performed each year [51]. 
 Lastly, the results of this study can be compared to the annual whole body radiation limits 
set forth as regulations or recommendations. However several different limits exist. The two 
general classifications of human exposures are radiation workers and the general public. The 
national radiation dose limits are set by the United States National Regulatory Commission (US 
NRC). The International Commission on Radiation Protection (ICRP) has recently published 
more recent recommendations for radiation dose limits which are more limiting than the US 
standards. It is important to note that the ICRP limits are only recommendations and that the US 
NRC regulates all radiation issues in the US. Table 15 summarizes the dose limits from both the 




Table 15: Annual Dose Limits for Radiation Workers and General Public 






from any One 
Procedure 
Occupational 3 20 mSv 50 mSv 0.0614 mSv 0.017 mSv 
Public 1 mSv 1 mSv - - 
 
The maximum cumulative dose recorded over the study (approximately one year in length) is 
only 0.1228% of the US NRC annual occupational dose limit and 0.307% of the more limiting 
ICRP annual occupational dose limit. Even the annual public limits are a factor of sixteen times 
greater than the maximum cumulative exposure anticipated for the 
64
Cu-ATSM canine imaging 
procedures. The maximum dose received per patient for by any of the workers involved in the 
study was 17 µSv. Thus, in order to exceed the annual international dose recommendation of 20 
mSv, a total of 1,177 
64
Cu-ATSM canine imaging procedures would need to occur each year or a 
total of 2,942 procedures to reach the annual legal dose limit of the US NRC.  
 When a patient is released from the nuclear recovery ward, the patient is still slightly 
radioactive. As mentioned previously, the patient is not released until the maximum surface dose 
rate was ≤ 17.5 µSv hr
-1
.  If an assumption was made that after the patient was released, the 
patient remained at a constant level of maximum dose rate, it would take a total of 57.15 hrs of 
direct physical contact in order for a member of the public to exceed the public dose limit of 1 
mSv. 
Future Work and Direction of Study 
 Because of the nature of this study, it will be impossible to eliminate the variability 
between procedures in future studies. Variability will always exist because of the differences 
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between patients including size, body composition, breed, tumor location, tumor grade, tumor 
type, anesthesia response, etc…In future studies, what should be focus on is minimizing the 
changes in the PET/CT procedures to attempt to make each procedure identical. During the 
seven procedures of this study, the PET/CT procedure was altered on three separate occasions, 
usually changing the length of the procedure. By keeping the PET/CT procedure set, this would 
reduce the amount of information that could be gathered from the study but would minimize the 
variance imaging procedures. 
 In addition, more data is needed for further analysis and comparison.  Because of the 
clinical nature of this study only seven dogs were enrolled which is a very small sample size. 
Statistical tests would perform better if there was a larger sample size to draw from and a larger 
sample size would also increase the statistical strength of the results.  
 One of the weaknesses of this study was that the main result of the study was the final 
cumulative exposure recorded by workers. This is an important result to obtain but it is also 
important to indentify during what duty the workers were exposed to radiation and this 
information was not recorded. If the study is to be continued or could be repeated, observing 
when the workers accumulate radiation exposure would be an equally interesting result to 










   





Cu-ATSM occupational doses in human/veterinary medicine, a 
comparison was made between the occupational veterinary exposures of 
64
Cu-ATSM and FDG 
human/veterinary medicine occupational exposures. In the comparison between 
64
Cu-ATSM 
veterinary occupational exposures and human medicine worker exposures from FDG, it was 
found that the occupational doses recorded in this study were slightly lower or equal to the 
occupational doses seen in human medicine (Table 10). This finding supports the hypothesis that 
despite the lower levels of radioactivity present in veterinary PET procedures, by anesthetizing 
patients there is a potential increase for higher radiation exposures to occupational workers. In 
the comparison between veterinary occupational exposures from FDG and 
64
Cu-ATSM, it was 
found that the veterinary occupational exposures from 
64
Cu-ATSM were equal to or less than the 
veterinary occupational exposures from FDG (Table 12), depending on the worker. This result 
was predicted in the hypothesis and can be attributed similarity of the procedures and the 














[1]  IAEA, "Radiation Protection in Newer Medical Imaging Techniques: PET/CT," 
International Atomic Energy Agency, Vienna, 2008. 
[2]  N. Martinez, S. Kraft, D. Gibbons, B. Arceneaux, J. Stewart, K. Mama and T. Johnson, 
"Occupational Per Patient Radiation Dose from a Conservative Protocol for Veterinary F-
18-Flurodeoxyglucose Positron Emission Tomography," Veterinary Radiology & 
Ultrasound, vol. 53, no. 5, pp. 591-597, 2012.  
[3]  M. M. Ter-Pogossian, M. E. Phelps, E. J. Hoffman and N. A. Mullani, "A Positron-
Emission Transaxial Tomograph for Nuclear Imaging (PETT)," Radiology, vol. 114, no. 1, 
pp. 89-98, 1975.  
[4]  M. E. Phelps, E. J. Hoffman, N. A. Mullani and M. M. Ter-Pogossian, "Application of 
Annihilation Coincidence Detection to Transaxial Reconstruction Tomography," Journal of 
Nuclear Medicine, vol. 16, no. 3, pp. 210-224, 1975.  
[5]  L. Schrevens, N. Lorent, C. Dooms and J. Vansteenkiste, "The Role of PET Scan In 
Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer," The Oncologist, 
vol. 9, pp. 633-643, 2004.  
[6]  M. Phelps, PET: Molecular Imaging and Its Biological Applications, New York: Springer, 
2004.  
[7]  A. K. LeBlanc and G. Daniel, "Advanced Imaging for Veterinary Cancer Patients," 
Veterinary Clinics Small Animal Practice, vol. 37, pp. 1059-1077, 2007.  
[8]  J. Lawrence, E. Rohren and J. Provenzale, "PET/CT TOday and Tomorrow in Veterinary 
Cancer Diagnosis and Monitoring: FUndamentals, Early Results, and Future Perspectives," 
Veterinary and Comparative Oncology, vol. 8, no. 3, pp. 163-187, 2012.  
[9]  R. J. Myerson, A. Singh, H. Bigott, B. Cha, J. Engelbach, J. Kim, W. Lamoreaux, E. Moros, 
P. Novak, T. Sharp, W. Straube, M. Welch and M. Xu, "Monitoring the Effect of Mild 
Hyperthermia on Tumour Hypoxia by Cu-ATSM PET Scanning," Journal of Hyperthermia, 
vol. 22, no. 2, pp. 93-115, 2006.  
[10]  J. Lewis, P. Herrero, T. Sharp, J. Engelbach, Y. Fujibayashi, R. Laforest, A. Kovacs, R. 
Gropler and M. Welch, "Delineation of Hypoxia in Canine Myocardium Using PET and Cu-




[11]  R. Laforest, F. Dehdashti, J. Lewis and S. Schwarz, "Dosimetry of Cu-60,61,62,64-ATSM: 
A Hypoxia Imaging Agent for PET," European Journal of Nuclear Medicine and Molecular 
Imaging, vol. 32, no. 7, pp. 764-770, 2005.  
[12]  H. Yuan, T. Schroeder, J. Bowsher, L. Hedlund, T. Wong and M. Dewhirst, "Intertumoral 
Differences in Hypoxia Selectivity of PET Imaging Agent CU-64-ATSM," Journal of 
Nuclear Medicine, vol. 47, no. 6, pp. 989-998, 2006.  
[13]  B. J. Fueger, J. Czernin, I. Hildebrandt, C. Tran, B. S. Halpern, D. Stout, M. E. Phelps and 
W. A. Weber, "Impact of Animal Handling on the Results of F-18-FDG Studies in Mice," 
Journal of Nuclear Medicine, vol. 47, no. 6, pp. 999-1006, 2006.  
[14]  J. Kim, H. Park, J. Lee, K. Kim, K. Lee, H. Ha, T. Choi, G. An and G. Cheon, "A Simple 
Cu-64 Production and Its Applications of Cu-64-ATSM," Applied Radiation and Isotopes, 
vol. 67, no. 7-8, pp. 1190-1194, 2009.  
[15]  D. Poon, P. Burns, M. Douglas, J. Zhang, J. Gaglani, W. Drost, K. Kumar, R. McKenney, 
N. Hall and M. Knopp, "PET for Pets: PET/CT Imaging of Veterinary Patients," Journal of 
Nuclear Medicine, vol. 51, no. 2, pp. 1028-1035, 2010.  
[16]  A. Hansen, F. McEvoy, S. Engelholm, I. Law and A. Kristensen, "FDG PET/CT Imaging in 
Canine Cancer Patients," Veterinary Radiology & Ultrasound, vol. 52, no. 2, pp. 201-206, 
2011.  
[17]  B. Kang, S. Kim, C. Lim, S. Gu, D. Jang, Y. Kim, D. Kim, E. Woo, Z. Cho and H. Park, 
"Correlation Between Fluorodeoxyglucose Positron Emission Tomography and Magnetic 
Imaging Findings of Non-Suppurative Meningoencephalitis in 5 Dogs," Canadian 
Veterinary Journal, vol. 51, no. 9, pp. 986-992, 2010.  
[18]  J. S. Mattoon and J. N. Bryan, "The Future of Imaging in Veterinary Oncology: Learning 
from Human Medicine," The Veterinary Journal, 2013.  
[19]  N. L. McElroy, "Worker Dose Analysis Based on Real Time Dosimetry," Health Physics, 
vol. 75, no. 5, pp. 608-609, 1998.  
[20]  N. A. Benatar, B. F. Cronin and M. J. O'Doherty, "Radiation Dose Rates from Patients 
Undergoing PET: Implications for Technologists and Waiting Areas," European Journal of 
Nuclear Medicine, vol. 27, no. 5, pp. 583-589, 2000.  
[21]  K. J. Carson, V. A. L. Young, V. P. Cosgrove, P. H. Jarritt and A. R. Hounsell, "Personal 
Radiation Dose Considerations in the Use of an Integrated PET-CT Scanner for 





[22]  C. Chiesa, V. De Sanctis, M. Schiavini, C. E. Fraigola, A. Bogni, C. Pascali, D. Decise and 
R. Marchesini, "Radiation Dose to Technicians Per Nuclear Medicine Procedure: 
Comparision between Technetium-99m, Gallium-67, and Iodine-131 Radiotraceers and 
Fluorine-18 Fluorodeoxyglucose," European Journal of Nuclear Medicine, vol. 24, no. 11, 
pp. 1380-1389, 1997.  
[23]  K. Dalianis, J. Malamitsi, L. Gogou, M. Pagou, R. Efthimiadou, J. Andreou, A. Louizï and 
E. Georgiou, "Dosimetric Evaluation of the Staff Working in a PET/CT Department," 
Nuclear instruments and Methods in Physics Research Section A: Accelerators, 
Spectrometers, Detectors and Associated Equipment, vol. 569, no. 2, pp. 548-550, 2006.  
[24]  B. Guillet, P. Quentin, S. Waultier, M. Bourrelly, P. Pisano and O. Mundler, "Technologist 
Radiation Exposure in Routine Clinical Proactice with 18F-FDG PET," Journal of Nuclear 
Medicine Technology, vol. 33, no. 3, pp. 175-179, 2005.  
[25]  S. Leide-Svegborn, "Radiation Exposure of Patients and Personnel from a PET/CT 
Procedure with 18F-FDG," Radiation Protection Dosimetry, vol. 139, no. 1-3, pp. 208-213, 
2010.  
[26]  S. Leide-Svegborn, "External Radiation Exposure of Personnel in Nuclear Medicine from 
18-F, 99m-Tc, and 131-I with Special Reference to Fingers. Eyes, and Thyroid," Radiation 
Protection Dosimetry, vol. 149, no. 2, pp. 196-206, 2011.  
[27]  V. A. McCormick and J. A. Miklos, "Radiation Dose to Positron Emission Tomography 
Technologists during Quantitative Versus Qualitative Studies," Journal of Nuclear 
Medicine, vol. 34, no. 5, pp. 769-772, 1993.  
[28]  F. Roberts, D. Gunawardana, K. Pathmaraj, A. Wallace, L. Paul, T. Mi, S. Berlangieri, G. 
O'Keefe, C. Rowe and A. Scott, "Radiation Dose to PET Technologists and Strategies to 
Lower Occupational Exposure," Journal of Nuclear Medicine, vol. 33, no. 1, pp. 44-47, 
2005.  
[29]  C. N. Robinson, J. G. Young, A. B. Wallace and V. J. Ibbetson, "A Study of the Personal 
Radiation Dose Received by Nuclear Medicine Technologists Working in a Dedicated PET 
Center," Health Physics, vol. 88, no. 2, pp. 17-21, 2005.  
[30]  T. Seierstad, E. Stranden, K. E. M. Bjering, A. Holt, H. M. Michalsen and O. Wetteland, 
"Doses to Nuclear Technicians in a Dedicated PET/CT Centre Utilising 18F 





[31]  D. Delbeke, R. E. Coleman, M. J. Guiberteau, M. L. Brown, B. A. Siegel, D. W. Townshed, 
L. L. Berland, J. A. Parker, K. Hubner, M. G. Stabin, G. Zubal, M. Kachelriess, V. Cronin 
and S. Holbrook, "Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0," 
Journal of Nuclear Imaging, vol. 47, no. 6, p. 903, 2006.  
[32]  P. Zanzonico, L. Dauer and J. S. Germain, "Operational Radiation Safety for PET-CT, 
SPECT-CT, and Cyclotron Facilities," Health Physics, vol. 95, no. 5, pp. 554-570, 2008.  
[33]  C. Cember and T. E. Johnson, Introduction to Health Physics, McGraw-Hill, 2009.  
[34]  E. J. Hall and A. J. Giaccia, Radiobiology for the Radiologist, Wolters Kluwer, 2012.  
[35]  B. N. Taylor and Thomson, "International System of Units (SI): National Institute of 
Standards and Technology Special Publication 330," 2008. 
[36]  United States Nuclear Regulatory Commission, "10 CRF 20.1004," USNRC, 2013. 
[37]  D. Griffiths, Introduction to Elementary Particles, Weinheim: WILEY-VCH Verlag GMBH 
& Co. KGaA, 2008.  
[38]  Philips Healthcare Systems, Gemini TF PET/CT with Truflight Technology, Koninklijke 
Philips Electronics, 2006.  
[39]  J. P. Holland, J. S. Lewis and F. Dehdashti, "Assessing Tumor Hypoxia by Positron 
Emission Tomography with Cu-ATSM," The Quarterly Journal of Nuclear Medicine and 
Molecular Imaging, no. 53, pp. 193-200, 2009.  
[40]  Y. Fujibayashi, H. Taniuchi, Y. Yohekura, H. Ohtani, J. Konishi and A. Yokoyama, 
"Copper-62-ATSM: A New hypoxia Imaging Agent with High Membrane Permeability and 
Low Redox Potential," Journal of Nuclear Medicine, no. 38, pp. 1155-1160, 1997.  
[41]  A. Obata, E. Yoshimi, A. Waki, J. Lewis, N. W. M. Oyama, H. Saji, Y. Yonekura and Y. 
Fujibayashi, "Retention Mechanism of Hypoxia Selective Nuclear 
Imaging/Radiotherapeutic Agent Cu-diacetyl-bis (N4-methylthiosemicarbazone) (Cu-
ATSM) in Tumor Cells," Annals of Nuclear Medicine, no. 15, pp. 499-501, 2001.  
[42]  J. Dearling, J. Lewis, D. McCarthy, M. Welch and P. Blower, "Redox-Active Metal 
Complexes for Imaging Hypoxic tissues: Structure-Activity Relationships," Chemical 




[43]  J. Dearling, J. Lewis, G. Mullen, M. Welch and P. Blower, "Copper(I) bis(diphosphine) 
Complexes as a Basis for Radiopharmaceuticals for Positron Emission Tomography and 
Targeted Radiotherapy," Chemical Communications, no. 7, pp. 249-59, 2002.  
[44]  R. Maurer, P. Blower, J. Dilworth, C. Reynolds, Y. Zheng and G. Mullen, "Studies on the 
Mechanism of Hypoxic Selectivity in Copper bis(thiosemicarbazone) Radiopharaceuticals," 
Journal of Nuclear Medical Chemistry, no. 45, pp. 1420-1431, 2002.  
[45]  M. G. Stabin, Radiation Protection and Dosimetry, New York City: Springer, 2007.  
[46]  M. Demir, B. Demir, D. Yasar, H. B. Sayman, M. Halac, A. S. Ahmed, K. Ozcan and I. 
Uslu, "Radiation Doses to Technologists Working with 18F-FDG in a PET Center with 
High Patient Capacity," Nukleonika, vol. 55, no. 1, pp. 107-112, 2010.  
[47]  T. Biran, J. Weininger, S. Malchi, R. Marciano and R. Chisin, "Measurements of 
Occupational Exposure for a Technologist Performing 18F FDG Scans," Health Physics, 
vol. 87, no. 5, pp. 539-544, 2004.  
[48]  National Research Council, Health Risks from Exposure to Low Levels of Ionizing 
Radiation: BEIR VII Phase 2, Washington, D.C.: The National Academic Press, 2006.  
[49]  International Comission on Radiation Protection, "Publication 103," Annals of the ICRP, 
vol. 37, no. 2-4, 2007.  
[50]  Nation Council on Radiation Protection & Measurements, NCRP Report No. 93: Ionizing 
Radiation Exposure of the Population of the United States, Bethesda, MD: NCRP, 1987.  
[51]  National Council on Radiation Protection & Measurements, NCRP Report No. 160: 
Ionizing Radiation Exposure of the Population of the United States, vol. Report 160, 
Bethesda, MD: NCRP, 2009.  
[52]  United Nations Scientific Committee on the Effects of Atomic Radiation, Sources and 
Effects of Ionizing Radiation: United Nations Scientific Committee on the Effects of 
Atomic Radiation: UNSCEAR 2008 Report to the General Assembly with Scientific 
Annexes, New York: United Nations, 2010.  
[53]  United Nations Scientific Committee on the Effects of Atomic Radiation, Sources and 
Effects of Ionizing Radiation: United Nations Scientific Committee on the Effects of 
Atomic Radiation: UNSCEAR 2000 Report to the General Assembly with Scientific 
Annexes, New York City: UNSCEAR, 2000.  













































































































All measurements will be made using DMC 2000S and DMC 2000XB brand of Electrical 
Personal Dosimeters or EPD. Each EPD was calibrated by Palo Verde Nuclear Generation 
Station to ANSI 4220A standards. The batteries of each EPD were changed in Aug of 2012 and 
each battery should last at least a full year.  
Before every treatment, ensure that the previous history on each individual EPD is properly 
analyzed, stored, and cleared. The EPDs should be placed into pause mode after the last 
treatment (there are three modes mentioned in for the EPDs and they are the following: pause, 
sleep, and active). To bring the EPDs out of pause mode, hold the enter button for a few seconds. 
This will bring the EPDs into active mode so that dose can be collected. It is recommended to 
turn the EPDs on just before use to minimize any interference.  
To ensure that background radiation is not a factor during the treatment, place the EPD 
labeled Control in room ACC 155 in the Southwest corner of the room to monitor any 
background radiation. 
The observer should record all information on the Dose Recording Spreadsheet, a copy of the 
spread sheet can be found in ACC 155 near the Southwest corner of the room. Any details that 
may change the dose distribution should also be reported on the spreadsheet as well. 
The radionuclide will be delivered to the Nuclear Medicine Lab ACC 159 at approximately 
10:00 am. The RCO officer who is picking up the 
64
Cu from FedEx will communicate with the 
group to alert them of its pending arrival. The EPD badges Prep C (to be worn on chest) and 
Prep W (to be worn on waist) are handed out to the person checking in the nuclide and preparing 
it for treatment. Record the time that the two EPDs are turned on and after the nuclide has been 




The patient should be transported from anesthesia to the PET/CT room. Record the time the 
patient arrives. 
2) DOSE FIELD MEASUREMENTS FROM THE ANIMAL: 
Depending on the situation, dose field measurements will be made around the patient during 
the post-injection time period using EPDs. The EPDs should not be activated until after the 
injection is made and the CT scan completed. DO NOT put the EPDs through the CT scan 
because this will add dose to the EPDs and might cause artifacts in the CT images. At this point, 
activate the following EPDs and place them directly on the patient: Head C, Right Shoulder C, 
Right Hip C, Left Hip C, Left Shoulder C, Head W. Below is a diagram showing approximately 
where to attach each EPD. During the PET scan, the region being imaged will have to be cleared 
of the EPDs because the EPDs distort the imaging. So the observer will have to enter the room 
several times to remove/reattach the EPD’s. Record the times that the EPD’s are activated, 
attached, unattached, and collected.  
 
 





There is an ion chamber located in the CT/PET control room (H106D). The ion chamber 
is a Fluke 451 Ion Chamber Survey Meter, Product #: 451P-RYR, Serial #: 0000003459. It was 
calibrated with a 
137
Cs source and it is accurate to within 10% up to 101 mR/hr. The last date of 
calibration was 11/21/12. Once the EPDs have been activated and placed onto the patient, use the 
ion chamber instrument to get surface and distance dose readings. To activate the ion chamber, 
just hold the power button then the instrument will display the exposure rate on the main screen. 
Record the exposure rate and the time of each record as well as the distance from the patient 
from the place of the ion chamber. The recommended exposure rate locations chosen for the ion 
chamber are shown on the diagram below.  Be sure to measure from the same location each time 
a measurement is taken and record the distance from the instrument to the patient. Due to the 
dynamic scans, the data can be collected when the location is not obstructed by the gantry head. 
 
Figure 26: Ion Chamber Measurement Locations for External Field Measurements 
3) PERSONNEL DOSES: 
Measure the dose to the person transporting the radiopharmaceutical from the hot lab to the 
PET/CT suite, injecting the nuclide into the patient, and then to that will be coming in contact 
with the anesthetized patient (anesthesia technologist, the surgeon and nuclear medicine 




record the activation time and activate the EPDs for each individual below. Activate just before 
the task starts and remove it and record the dose once that task is completed, as follows: 
Transport C and Transport W – this pair of EPDs should be activated and then recovered to 
measure the dose experienced by the person transporting the radiopharmaceutical from Nuclear 
Medicine to the PET/CT room. 
Anesth C and Anesth W – Activate these EPDs when the animal is being injected, and do not 
collect after the anesthetist will no longer be exposed, after imaging is completed and the animal 
is recovered from anesthesia. Whenever the anesthetist enters and leaves the PET/CT room, 
record the time. 
Surgeon C and Surgeon W – This pair of EPDs should be worn by the person extracting the 
tissue sample from the tumor. Activate the badge just before the action takes place the time 
period that the EPD is in use.  
Nuc Med 1 C, Nuc Med 1 W, Nuc Med 2 C, and Nuc Med 2 W are given to PET/CT 
technicians, who may also be exposed if they have to enter the PET/CT treatment room to 
interact with the equipment or the animal. So two of these badges are reserved for these 
personnel. Record any time that either of the technicians enters the PET/CT room and collect the 
EPD’s after imaging and anesthetic recovery are completed. 
Once imaging is complete, the animal is transported back to the nuclear medicine ward 
located in room ACC 162 and woken up from the anesthetic.  This will require the Anesthesia 
and nuclear medicine technologists, so those personnel measurements need to be continued until 
the animal can be left alone.  Make sure to record all of the relevant times (time of transport, 





4) DATA COLLECTION AND STORAGE: 
After completion of the whole process, the observer should ensure that all the EPD 
badges have been collected from all personnel. Each cumulative dose reading from every EPD 
should be recorded. Also, the observer should record the cumulative dose readings on the six 
EPDs that were placed in the PET/CT room on the spreadsheet along with the other readings, 
occurrences, and all the recorded times.  
Now that all the doses are recorded in the EPDs, the data must be saved, the EPDs must 
be cleared for re-use, and each EPD must be put back into pause mode for the next treatment use. 
To do this, open up the software Dosimass. One of the tabs at the top of the program’s menus is 
Administration. Under this tab is the option to Log in and Register. Click on this option. The user 
name is supervisor and the password is also supervisor. 
Once the observer has logged into the software, attach the scanner into the port that was 
configured to use the scanner. Now click on the menu tab labeled Dosimeter. Under this tab is 
the option of Entry/Exit. Click on this option. Now each EPD can be placed in pause mode by 
scanning the dosimeter by placing the EPD directly in front of the scanner then clicking on the 
Exit button. There is an option in to read another EPD, so after clicking on the Exit button repeat 
until all EPDs have been read and exited. This step will place the EPDs in the sleep mode. 
Once the EPDs have been placed in sleep mode, go back to the top tab that reads 
Dosimeter and click on it. There will be an option labeled History. Click on this and place an 
EPD to be read in front of the scanner then click on the “Play” button located at the bottom of the 
screen. This will display the history of the EPD. To save the history, click on the floppy disk 




this step until all the EPDs histories have been saved. It is recommend to save each text file with 
a name to reflect the date of treatment and which EPD. An example is like 1-15-13 Head C. 
Enter into each EPD and double check that all recorded dose has been removed to ensure 
the EPDs have been cleared. The program should show you that there is no dose recorded on the 
EPD if the process above was done properly. Then click Exit to put the EPD back into sleep 
mode. Then scan the next EPD and repeat the process.  
After the EPDs have been cleared, place them into pause mode. This can be done by 
selecting Dosimeter -> Single Configuration and reading in an EPD. Then select the box that 
reads Enable Pause Mode and click Write Dosimeter. Repeat this process for each EPD and this 
































































ACRONYMS AND ABBREVIATIONS 
 
ACC     Animal Cancer Center 
Bq     Becquerel 
BEIR     Biological Effects of Ionizing Radiation 
CT     Computation Tomography 
CSU     Colorado State University 
EPD     Electronic Personal Dosimeter 
FDG     Fludeoxyglucose 
ICRP     International Commission on Radiation Protection 
Kg     Kilogram 
LNT     Linear No-Threshold 
Lutetium Yttrium Oxyorthosilicate LYSO 
MRI     Magnetic Resonance Imaging 
PET     Positron Emission Tomography 
PET/CT    Combined PET and CT imaging 
PMT     Photomultiplier Tube    
Rad     Radiation Absorbed Dose 
Rem     Roentgen Equivalent Man 
ROI     Region of Interest 
Sv     Sievert 
US NRC    United States Nuclear Regulatory Commission 
VTH      James L. Voss Veterinary Teaching Hospital 
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